PeproMene, Bio PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia in the Phase 1 Clinical Trial of PMB-CT01 at City of Hope
07.08.2025 - 18:06:45
PeproMene Bio, Inc. California